{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:26:28Z","timestamp":1777857988165,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T00:00:00Z","timestamp":1229040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>Abstract<\/jats:p>\n                  <jats:p>Paroxetine is widely prescribed because it has the indication for multiple psychiatric disorders. Our objective was to assess the effect of short-term administration of paroxetine on low-density lipoprotein cholesterol (LDL-C) levels in both healthy controls (HCs) and in patients with panic disorder (PD). Blood samples for measurement of LDL-C were collected atbaseline, after 8\u00a0weeks of paroxetine administration and post-discontinuation in 24 male HCs and nine male patients suffering from PD, for a total of 33 subjects. Paroxetine treatment, both in HCs and PD patients, induced a mean 9% increase per subject in LDL-C that normalized post-discontinuation, suggesting causality. The National Cholesterol Education Program (NCEP) guidelines suggest that this paroxetine-induced increase in LDL-C is clinically significant but would not warrant therapeutic intervention in this population selected to be at low cardiovascular risk. However, the increase in LDL-C levels raised above the threshold of 2.7\u00a0mmol\/L (100\u00a0mg\/dL) in 36% of our low-risk subjects. The LDL-C increase in this subgroup would be associated with a minor increase in coronary heart disease (CHD) risk. A similar 9% paroxetine-induced increase in LDL-C observed in the large number of psychiatric patients suffering from comorbid established CHD would be detrimental from a cardiovascular perspective and would oppose the new NCEP therapeutic goals of decreasing LDL-C levels by 30\u201340% in high and moderately high-risk patients. It is possible that longer treatment duration and use of higher doses of paroxetine would lead to a greater increase in LDL-C.<\/jats:p>","DOI":"10.1177\/0269881108094320","type":"journal-article","created":{"date-parts":[[2008,12,12]],"date-time":"2008-12-12T21:36:32Z","timestamp":1229117792000},"page":"826-830","source":"Crossref","is-referenced-by-count":18,"title":["Paroxetine-induced increase in LDL cholesterol levels"],"prefix":"10.1177","volume":"23","author":[{"given":"JM","family":"Le Melledo","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Mailo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Lara","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MC","family":"Abadia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Van Ameringen","sequence":"additional","affiliation":[{"name":"Anxiety Disorders Clinic, McMaster University Medical Centre, Department of Psychiatry and Behavioural Neurociences, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Perez-Parada","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,12,12]]},"reference":[{"key":"atypb1","volume-title":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200306000-00016"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114163"},{"key":"atypb4","first-page":"5S","volume":"46","author":"Canadian Psychiatric Association","year":"2001","journal-title":"Can J Psychiatry"},{"key":"atypb5","first-page":"27","volume":"65","author":"Casey DE","year":"2004","journal-title":"JClin Psychiatry"},{"key":"atypb6","first-page":"10","volume":"19","author":"Cavallucci S","year":"2004","journal-title":"Pharmacy Practice"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.001"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1209"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.2.190"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0213"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(03)00569-9"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1017\/S109285290000691X"},{"key":"atypb13","unstructured":"Psychopharmacology Bulletin (2003) 37 (Suppl.)."},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000138764.31106.60"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(03)00587-0"},{"key":"atypb16","first-page":"3144","volume":"106","author":"Third Report on the National Cholesterol Education Program Expert Panel on Detection","year":"2002","journal-title":"Circulation"},{"key":"atypb17","first-page":"E1101","volume":"269","author":"Tonolo G","year":"1995","journal-title":"AmJ Physiol"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114086"},{"key":"atypb19","unstructured":"Wyeth revised monograph 2003."},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(97)00134-7"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108094320","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108094320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:05:23Z","timestamp":1777507523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881108094320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,12]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1177\/0269881108094320"],"URL":"https:\/\/doi.org\/10.1177\/0269881108094320","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,12]]}}}